story of the week
ASCO 2020: Adjuvant Osimertinib Therapy Dramatically Improves Outcomes in Non–Small Cell Lung Cancer
Disease-free survival was so much greater among patients who took the drug for up to 3 years that the study was unblinded early
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.